Apollo Hospitals Enterprise Ltd Q3 FY26 Earnings Analysis
Published 3 Aug 2026 | Healthcare Services | Market Cap: ₹1.2L Cr
Price
₹8,820
Market Cap
₹1.2L Cr
P/E Ratio
64.0
Earnings Summary
- Healthcare Services revenue is expected to grow at 13% organically in existing beds over the next 2-3 years, with an additional 5% growth anticipated from new bed additions in the next two years. - Base hospital network margins were around INR 10-15 crore costs built into Q2 FY26, equating to roughly 50 basis points of revenue, with margins already above 25% excluding new beds.
📊 Revenue & Sales Performance
- Healthcare Services revenue is expected to grow at 13% organically in existing beds over the next 2-3 years, with an additional 5% growth anticipated from new bed additions in the next two years. (Page 13) - Apollo HealthCo's revenues grew 18% YoY, supported by an 18% growth in AHLL, indicating strong growth momentum. (Page 3) - Digital business GMV (Gross Merchandise Value) growth is targeted between 25%-30% overall, with pharmacy business growing at ~30% YoY and quarter-on-quarter growth of around 5%-7%. Insurance and diagnostics businesses are also set to pick up from Q4 onwards. (Page 6) - New hospitals additions: Six new hospitals are planned with phased commissioning from Q3 FY26 to Q1 FY27, expected to contribute to revenue growth. (Page 3) - Improvements in case mix and patient complexity are driving average revenue per patient growth rather than tariff increases. (Page 14) - Occupancy is targeted to improve to around 70%, supporting volume growth. (Page 11)
📈 Profitability & Margins
- Base hospital network margins were around INR 10-15 crore costs built into Q2 FY26, equating to roughly 50 basis points of revenue, with margins already above 25% excluding new beds. - The company expects existing hospital EBITDA margins to expand by up to 500 basis points over the next one to two years, targeting margins above 25%. - The established hospitals reported 24.6% EBITDA margin in Q2 FY26, with an internal target to increase it further. - Overall EBITDA losses from new hospitals are expected up to INR 150 crore for FY27 but these are expected to breakeven within 12 months of commissioning. - Cost-cutting measures targeting INR 120 crore reduction, with INR 60 crore achieved, are supporting margin expansion. - Digital and AI initiatives are expected to drive operational efficiencies and improve profitability. - Hospital organic growth expected to return to ~30%, aided by market expansions and recovery in international patient flows.
🏗️ Capital Expenditure Plans
- Six new hospitals are planned to be added between FY26 and FY27, with Pune and Defense Colony hospitals already soft commissioned in Q3 FY26. - Sarjapur Bangalore and Calcutta hospitals are expected to start in Q4 FY26. - Hyderabad and Gurugram hospitals anticipated around Q1 FY27 with enhanced facilities including comprehensive oncology programs. - Brownfield expansions underway at Jubilee Hills and Secunderabad. - Investment in new technologies and clinical programs, including AI interventions in oncology, radiology, and stroke care. - Continued expansion of Apollo 24/7 digital platform and related capabilities. - Hiring planned ahead of hospital openings (e.g., Pune, Gurgaon) with some ramp-up costs captured in Q2 FY26. - Focus on improving existing hospital utilization and EBITDA margins while managing losses from new hospitals capped at INR 150 crore for FY27.
💰 Fundraising & Capital Structure
- The transcript does not explicitly mention any current or planned new fundraising through debt or equity. - There is a focus on disciplined execution, cost management, and organic growth to fund expansions. - Management highlights strong cash flows and cost-cutting initiatives (INR 120 crore planned savings) to support growth and margin improvement. - Investments are being made in hospital expansions, digital platforms, and insurance businesses, but these appear funded through internal accruals and existing resources. - No explicit mention of raising capital via debt or equity in the near term during the Q2 FY26 earnings call.
📋 Order Book & Pipeline
The transcript does not explicitly mention current or expected orderbook or pending orders for Apollo Hospitals (AHEL). However, related capacity expansion and hospital commissioning plans were discussed: - Six new hospitals are planned for commissioning across FY26 and FY27, staggered across Q3, Q4, and Q1. - Soft commissioning of Defense Colony Cancer Hospital and Pune hospital started in Q3. - Sarjapur Bangalore and Calcutta hospitals are expected to start in Q4. - Hyderabad and Gurugram hospitals planned by early Q1 with expanded oncology and private room facilities. - Brownfield projects for Jubilee Hills and Secunderabad are underway. - The focus is on organic growth including 13% growth in Healthcare Services from existing beds plus 5% additional growth from new bed additions over the next 2 years. No direct reference to orderbook or pending orders was provided in the available transcript pages.
Key Metrics
Frequently Asked Questions
What were Apollo Hospitals Enterprise Ltd Q3 FY26 results?
- Healthcare Services revenue is expected to grow at 13% organically in existing beds over the next 2-3 years, with an additional 5% growth anticipated from new bed additions in the next two years. - Base hospital network margins were around INR 10-15 crore costs built into Q2 FY26, equating to roughly 50 basis points of revenue, with margins already above 25% excluding new beds.
What is Apollo Hospitals Enterprise Ltd share price analysis?
Apollo Hospitals Enterprise Ltd currently shows a neutral. The stock trades at a P/E of 64.0 with a market cap of ₹116,214. Investors should review the full earnings analysis for detailed insights.
Is Apollo Hospitals Enterprise Ltd planning capital expenditure?
- Six new hospitals are planned to be added between FY26 and FY27, with Pune and Defense Colony hospitals already soft commissioned in Q3 FY26.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
